MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596343 | Name: Neostigmine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Neostigmine is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.

Chemical Structure

Neostigmine
Neostigmine
CAS#59-99-4

Theoretical Analysis

MedKoo Cat#: 596343

Name: Neostigmine

CAS#: 59-99-4

Chemical Formula: C12H19N2O2+

Exact Mass: 223.1441

Molecular Weight: 223.29

Elemental Analysis: C, 64.55; H, 8.58; N, 12.55; O, 14.33

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Neostigmine; CCRIS 3079; Juvastigmin; Eustigmin; Eustigmine; Intrastigmina;
IUPAC/Chemical Name
3-((dimethylcarbamoyl)oxy)-N,N,N-trimethylbenzenaminium
InChi Key
ALWKGYPQUAPLQC-UHFFFAOYSA-N
InChi Code
InChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1
SMILES Code
C[N+](C)(C1=CC=CC(OC(N(C)C)=O)=C1)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 223.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zhang X, Jiang H, Li S, Luo A, Zhao Y. Use of low-dose neostigmine intravenously in the treatment of thyroid storm-induced severe tachycardia in patient during huge pelvic mass resection: A case report and review of literature. Medicine (Baltimore). 2018 Apr;97(14):e0300. doi: 10.1097/MD.0000000000010300. Review. PubMed PMID: 29620652; PubMed Central PMCID: PMC5902261. 2: Adeyinka A, Kondamudi NP. Cholinergic Crisis. 2018 Feb 25. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK482433/ PubMed PMID: 29494040. 3: Carron M, Bertoncello F, Ieppariello G. Profile of sugammadex for reversal of neuromuscular blockade in the elderly: current perspectives. Clin Interv Aging. 2017 Dec 22;13:13-24. doi: 10.2147/CIA.S134108. eCollection 2018. Review. PubMed PMID: 29317806; PubMed Central PMCID: PMC5743185. 4: El Harrad L, Bourais I, Mohammadi H, Amine A. Recent Advances in Electrochemical Biosensors Based on Enzyme Inhibition for Clinical and Pharmaceutical Applications. Sensors (Basel). 2018 Jan 9;18(1). pii: E164. doi: 10.3390/s18010164. Review. PubMed PMID: 29315246; PubMed Central PMCID: PMC5795370. 5: Hristovska AM, Duch P, Allingstrup M, Afshari A. The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis. Anaesthesia. 2018 May;73(5):631-641. doi: 10.1111/anae.14160. Epub 2017 Dec 27. Review. PubMed PMID: 29280475. 6: Neely GA, Kohli A. Neostigmine. 2017 Nov 26. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK470596/ PubMed PMID: 29261883. 7: Iwasaki H, Renew JR, Kunisawa T, Brull SJ. Preparing for the unexpected: special considerations and complications after sugammadex administration. BMC Anesthesiol. 2017 Oct 17;17(1):140. doi: 10.1186/s12871-017-0429-9. Review. PubMed PMID: 29041919; PubMed Central PMCID: PMC5645926. 8: Vazquez-Sandoval A, Ghamande S, Surani S. Critically ill patients and gut motility: Are we addressing it? World J Gastrointest Pharmacol Ther. 2017 Aug 6;8(3):174-179. doi: 10.4292/wjgpt.v8.i3.174. Review. PubMed PMID: 28828195; PubMed Central PMCID: PMC5547375. 9: Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017 Aug 14;8:CD012763. doi: 10.1002/14651858.CD012763. Review. PubMed PMID: 28806470. 10: Kelly A, Tran Q. The Optimal Pain Management Approach for a Laboring Patient: A Review of Current Literature. Cureus. 2017 May 10;9(5):e1240. doi: 10.7759/cureus.1240. Review. PubMed PMID: 28620569; PubMed Central PMCID: PMC5467776. 11: Bazerbachi F, Haffar S, Szarka LA, Wang Z, Prokop LJ, Murad MH, Camilleri M. Secretory diarrhea and hypokalemia associated with colonic pseudo-obstruction: A case study and systematic analysis of the literature. Neurogastroenterol Motil. 2017 Nov;29(11). doi: 10.1111/nmo.13120. Epub 2017 Jun 5. Review. PubMed PMID: 28580600. 12: Fuchs-Buder T, Schmartz D. [Residual neuromuscular blockade]. Anaesthesist. 2017 Jun;66(6):465-476. doi: 10.1007/s00101-017-0325-1. Review. German. Erratum in: Anaesthesist. 2017 Aug;66(8):578. PubMed PMID: 28573344. 13: Carron M, Zarantonello F, Lazzarotto N, Tellaroli P, Ori C. Role of sugammadex in accelerating postoperative discharge: A meta-analysis. J Clin Anesth. 2017 Jun;39:38-44. doi: 10.1016/j.jclinane.2017.03.004. Epub 2017 Mar 23. Review. PubMed PMID: 28494905. 14: Howard J, Wigley J, Rosen G, D'mello J. Glycopyrrolate: It's time to review. J Clin Anesth. 2017 Feb;36:51-53. doi: 10.1016/j.jclinane.2016.09.013. Epub 2016 Nov 18. Review. PubMed PMID: 28183573. 15: Ismail ZB. Epidural analgesia in cattle, buffalo, and camels. Vet World. 2016 Dec;9(12):1450-1455. doi: 10.14202/vetworld.2016.1450-1455. Epub 2016 Dec 19. Review. PubMed PMID: 28096620; PubMed Central PMCID: PMC5234062. 16: Carron M, Zarantonello F, Tellaroli P, Ori C. Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials. J Clin Anesth. 2016 Dec;35:1-12. doi: 10.1016/j.jclinane.2016.06.018. Epub 2016 Aug 4. Review. PubMed PMID: 27871504. 17: Tobias JD. Current evidence for the use of sugammadex in children. Paediatr Anaesth. 2017 Feb;27(2):118-125. doi: 10.1111/pan.13050. Epub 2016 Nov 17. Review. Erratum in: Paediatr Anaesth. 2017 Jul;27(7):781. PubMed PMID: 27859917. 18: Fuchs-Buder T, Nemes R, Schmartz D. Residual neuromuscular blockade: management and impact on postoperative pulmonary outcome. Curr Opin Anaesthesiol. 2016 Dec;29(6):662-667. Review. PubMed PMID: 27755128. 19: Parthasarathy S, Sripriya R, Krishnaveni N. Anesthetic management of intestinal obstruction: A postgraduate educational review. Anesth Essays Res. 2016 Sep-Dec;10(3):397-401. Review. PubMed PMID: 27746522; PubMed Central PMCID: PMC5062241. 20: Thilen SR, Bhananker SM. Qualitative Neuromuscular Monitoring: How to Optimize the Use of a Peripheral Nerve Stimulator to Reduce the Risk of Residual Neuromuscular Blockade. Curr Anesthesiol Rep. 2016;6:164-169. Epub 2016 Mar 22. Review. PubMed PMID: 27524943; PubMed Central PMCID: PMC4963456.